title: Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test.
abstract: In order to evaluate the utility of the mouse lymphoma assay (MLA) for detecting in vitro clastogens and spindle poisons and to compare it with the in vitro chromosomal aberration test (CA), we conducted an international collaborative study of the MLA that included 45 Japanese laboratories and seven overseas laboratories under the cooperation of the Ministry of Health and Welfare of Japan and the Japanese Pharmaceutical Manufacturer's Association. We examined 40 chemicals; 33 were reportedly positive in the CA but negative in the bacterial reverse mutation assay, six were negative in both assays and one was positive in both. We assayed mutations of the thymidine kinase (TK) locus (tk) of L5178Y tk +/- mouse lymphoma cells using the microwell method. According to our standard protocol, cells were exposed to the chemical for 3 h, cultured for 2 days and TK-deficient mutants were expressed in 96-well plates under trifluorothymidine. Each chemical was coded and tested by two or three laboratories. Among the 34 CA-positive chemicals, positive MLA results were obtained for 20 and negative results were obtained for nine. The remaining five chemicals were inconclusive or equivocal because of discrepant inter-laboratory results or reproduced discrepant results, respectively. Among the six CA-negative chemicals, one was negative in the MLA, two were positive and three were inconclusive. Thus, the MLA could detect only 59% (20/34) of CA-positive chemicals. We concluded that the MLA was not as sensitive as the CA. Some MLA-negative chemicals evoked positive responses in the CA only after long continuous treatment. These might also be genotoxic in the MLA with long continuous treatment. Improvement of the MLA protocol, including alteration of the duration of the treatment, might render the MLA as sensitive as the CA.
authors.affiliation: Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Honma
authors.forename: M
authors.initials: M
authors.lastname: Hayashi
authors.forename: H
authors.initials: H
authors.lastname: Shimada
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Wakuri
authors.forename: T
authors.initials: T
authors.lastname: Awogi
authors.forename: K I
authors.initials: KI
authors.lastname: Yamamoto
authors.forename: N
authors.initials: N
authors.lastname: Kodani
authors.forename: Y
authors.initials: Y
authors.lastname: Nishi
authors.forename: M
authors.initials: M
authors.lastname: Nakadate
authors.forename: T
authors.initials: T
authors.lastname: Sofuni
mesh_terms: D000818:Animals; D002869:Chromosome Aberrations / Q000235:genetics*; D004273:DNA, Neoplasm / Q000032:analysis; D005069:Evaluation Studies as Topic; D007940:Leukemia L5178 / Q000201:enzymology* / Q000235:genetics*; D051379:Mice; D009152:Mutagenicity Tests / Q000295:instrumentation / Q000379:methods*; D009153:Mutagens / Q000494:pharmacology; D013937:Thymidine Kinase / Q000172:deficiency / Q000235:genetics*; D014407:Tumor Cells, Cultured
chemical_list: D004273:DNA, Neoplasm; D009153:Mutagens; D013937:Thymidine Kinase